. Author manuscript; available in PMC: 2024 Mar 1.

Published in final edited form as: Ultrasound Obstet Gynecol. 2023 Mar;61(3):325–332. doi: 10.1002/uog.26100

Table 3.

Cost-effectiveness analysis of first-trimester cell-free DNA (cfDNA) screening for aneuploidy, based on screening strategy involving first-trimester ultrasound before cfDNA and strategy encompassing cfDNA only

Strategy	Cost (USD)	Effectiveness (QALY)	Cost-effectiveness ratio (USD/QALY)	ICER (USD/QALY gained)	NMB^*

Ultrasound before cfDNA	5215.95	0.295	17706.99	12588.83	24 241.03
cfDNA only	4672.27	0.251	18 586.28	—	20 466.01

Assuming willingness-to-pay of 100 000 US dollars (USD) per quality-adjusted life year (QALY). ICER, incremental cost-effectiveness ratio; NMB, net monetary benefit.